Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IQVIA HoldingsLTS:0JDM -0.67%86 Forward PE Ratio is 16.11 as of Jul. 21, 2026. GuruFocus rates LTS:0JDM with a GF Score™ of 86/100 and a GF Value™ of $249.15 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 87 Medical Diagnostics & Research companies, IQVIA Holdings ranks better than 71.26% on this metric.
IQVIA Holdings (LTS:0JDM) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
IQVIA Holdings Forward PE Ratio Related Terms
IQVIA Holdings Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for IQVIA Holdings's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IQVIA Holdings Forward PE Ratio Chart
IQVIA Holdings Annual Data
Trend
2019-12
2020-12
2021-12
2024-12
2025-12
Forward PE Ratio
21.60
22.27
25.97
16.64
17.47
IQVIA Holdings Quarterly Data
2019-06
2019-09
2019-12
2020-03
2020-06
2020-09
2020-12
2021-03
2021-06
2021-09
2021-12
2024-06
2024-09
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
Forward PE Ratio
24.69
20.96
21.60
15.60
23.31
19.57
22.27
23.47
28.57
26.18
25.97
19.16
18.69
16.64
15.00
13.35
13.84
17.47
13.02
LTS:0JDM vs WAT, ILMN, NTRA: Forward PE Ratio Comparison
For the Diagnostics & Research subindustry, IQVIA Holdings's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IQVIA Holdings Forward PE Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IQVIA Holdings's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where IQVIA Holdings's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
IQVIA Holdings (LTS:0JDM) has a Forward PE Ratio of 16.11 as of Jul. 21, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on IQVIA Holdings and its competitors. According to the industry distribution chart, IQVIA Holdings ranks #25 out of 87 companies in the Medical Diagnostics & Research industry, placing it in the top 28.7%.
Is IQVIA Holdings' Forward PE Ratio too high?
IQVIA Holdings' current Forward PE Ratio is 16.11. The Medical Diagnostics & Research industry median Forward PE Ratio is 22.50. IQVIA Holdings' value of 16.11 is 28.4% below this industry median. Based on the distribution chart, IQVIA Holdings ranks #25 out of 87 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, IQVIA Holdings has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IQVIA Holdings' Forward PE Ratio compare to WAT and ILMN?
According to the Medical Diagnostics & Research industry distribution chart, IQVIA Holdings ranks #25 out of 87 companies for Forward PE Ratio. This puts IQVIA Holdings in the upper half of its industry. The industry median Forward PE Ratio is 22.50. IQVIA Holdings' value of 16.11 is 28.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Diagnostics & Research company?
The median Forward PE Ratio among Medical Diagnostics & Research companies is 22.50, based on 87 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IQVIA Holdings's current Forward PE Ratio of 16.11 is 28.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on IQVIA Holdings and its competitors. For the Medical Diagnostics & Research industry, the median Forward PE Ratio is 22.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IQVIA Holdings's current Forward PE Ratio is 16.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IQVIA Holdings stock overvalued right now?
Based on GuruFocus' analysis, IQVIA Holdings (LTS:0JDM) is currently considered Modestly Undervalued. The stock's GF Value™ is $249.15, compared to a current price of $204.85 — trading 17.8% below its estimated fair value. The current Forward PE Ratio is 16.11 and 28.4% below the Medical Diagnostics & Research industry median of 22.50. IQVIA Holdings' overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For IQVIA Holdings (LTS:0JDM), the current Forward PE Ratio is 16.11 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IQVIA Holdings (LTS:0JDM) Overvalued in 2026?
Based on GuruFocus' analysis, IQVIA Holdings stock appears to be undervalued.
The current stock price of $204.85 is trading 17.8% below its estimated GF Value™ of $249.15.
GuruFocus considers IQVIA Holdings to be Modestly Undervalued.
Key valuation signals for LTS:0JDM:
Forward PE Ratio: 16.11
GF Value™: $249.15 vs. price of $204.85 (17.8% below fair value)
Industry Position: 28.4% below the Medical Diagnostics & Research median (#25 of 87)
No single metric tells the full story. See the LTS:0JDM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
86GF Score
Get the complete analysis for LTS:0JDM
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0JDM has been successfully added to your 
